Overview
IOVA market data
Price History
IOVA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.09 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.68 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.76 – $5.63 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2.2K · P/B 1.55 · P/S 7.82.
Company news
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Globenewswire Inc · Jul 17, 2026, 10:31 PM
8-K filing — IOVANCE BIOTHERAPEUTICS, INC. (IOVA)SEC EDGAR · Jul 2, 2026, 9:01 PM
Iovance Biotherapeutics Files Prospectus For Offering Mixed Shelf; Terms UndisclosedBenzinga · Jun 18, 2026, 8:40 PM
Iovance Biotherapeutics Says Therapeutic Goods Administration Of Australia Grants Approval With Conditions Of Amtagvi, Tumor-Derived Autologous T Cell Immunotherapy, For Previously Treated Advanced MelanomaBenzinga · Jun 3, 2026, 8:15 PM
Iovance Biotherapeutics Announces Allowance To Proceed From FDA For Investigational New Drug Application For Phase 1/2 Basket Study Of IOV-5001Benzinga · Jun 1, 2026, 11:41 AM